Cited by 119Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and TreatmentsInflammatory Bowel Disease

Primary sclerosing cholangitis: diagnosis, prognosis, and management

Open access
Singh, Siddharth, Talwalkar, Jayant A.·2013·Clinical Gastroenterology and Hepatology

Abstract

Primary sclerosing cholangitis (PSC) is a chronic immune-mediated disease of the liver of unclear etiology, characterized by chronic inflammation and fibrosis of bile ducts. It primarily affects middle-aged men and is associated with 4-fold increased mortality as compared with an age- and sex-matched population. Progressive biliary and hepatic damage results in portal hypertension and hepatic failure in a significant majority of patients over a 10- to 15-year period from the initial diagnosis. In addition, PSC confers a markedly increased risk of hepatobiliary cancer, including cholangiocarcinoma and gallbladder cancer, as compared with the general population, and cancer is the leading cause of mortality in patients with PSC. It is associated with inflammatory bowel disease in 70% of patients and increases the risk of colorectal cancer almost 10-fold. Despite significant research efforts in this field, the pathogenic mechanisms of PSC are still incompletely understood, although growing evidence supports the role of genetic and immunologic factors. There are no proven medical therapies that alter the natural course of the disease. Thus, liver transplantation is the only available treatment for patients with advanced PSC, with excellent outcomes in this population.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2013.02.016

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a small percentage of patients, clinically significant portal hypertension in PSC may occur early in the disease course, even in people with PSC with F2 or F3 fibrosis in the absence of full-blown histologic cirrhosis.

    “In a small percentage of patients, CSPH in PSC (in analogy to PBC) may occur early in the disease course, i.e. even in people with PSC with F2 or F3 fibrosis in the absence of full-blown histologic cirrhosis.250”

    From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [250]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Karlsen TH. The Nordic liver transplant registry. Annu Rep 2009; 2012:2009.
  2. Bangarulingam SY, Gossard AA, Petersen BT, et al. Complica- tions of endoscopic retrograde cholangiopancreatography in pri- mary sclerosing cholangitis. Am J Gastroenterol 2009;104: 855-860.

Cited by

Sorted by citations

Authors
Singh, S., & Talwalkar, J. A.
Affiliations
Mayo Clinic (US)
Corresponding author
Talwalkar, Jayant A.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2013-08
Volume
11
Issue
8
Pages
898-907
ISSN
1542-3565 (ISSN-L)
OpenAlex
W2076789082
Cited by
119
References
114
Citations by year
2026: 6 · 2025: 8 · 2024: 6 · 2023: 9 · 2022: 8 · 2021: 5 · 2020: 8 · 2019: 7 · 2018: 10 · 2017: 11 · 2016: 9 · 2015: 13 · 2014: 13 · 2013: 6
FWCI
1.74
Type
journal article
Language
en
Open access
Locations
  • Clinical Gastroenterology and Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK056924)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
Keywords
primary sclerosing cholangitis, bile duct inflammation, liver fibrosis, portal hypertension, hepatobiliary cancer, cholangiocarcinoma, gallbladder cancer, inflammatory bowel disease, colorectal cancer risk, liver transplantation, prognosis, pathogenesis, immune-mediated liver disease
MeSH terms
Bile Ducts, Gallbladder Neoplasms, Humans, Hypertension, Portal, Liver Neoplasms, Prognosis, Cholangitis, Sclerosing, Liver Transplantation, Liver Failure, Cholangiocarcinoma

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review